Myelofibrosis treatment
JAK inhibitors and newer drugs in myelofibrosis.
Key point
Ruxolitinib-based combination regimens showed improved spleen and symptom responses with acceptable safety, with efficacy significantly influenced by prior JAK inhibitor exposure.
From: Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis (Ann Med, 2026 Dec) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 15, 12, 13, 8, 18.
New guidelines and consensus this year
All papers from the last 12 months
147 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Outcomes of patients with myelofibrosis treated with ruxolitinib and anemia-supporting medicationsHematology2026 Dec 31PMID 42698151RCT
- Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective studyHematology2026 Dec 31PMID 42237068
- Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysisAnn Med2026 DecPMID 41761659Meta-analysisSystematic review
- Heme oxygenase-1/CO signaling suppresses NLRP3 inflammasome-mediated stromal fibrosis in primary myelofibrosisFree Radic Biol Med2026 NovPMID 42476324
- Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the SIMPLIFY-1 and MOMENTUM TrialsEur J Haematol2026 NovPMID 42452788RCT
- TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisBlood2026 Oct 15PMID 42378247RCT
- Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studiesLeuk Lymphoma2026 Oct 7PMID 42842696
- Peri-transplant ruxolitinib in myelofibrosis patients undergoing αβTCR and CD19-depleted stem cell transplantationBone Marrow Transplant2026 Oct 6PMID 42839031
- Practical Management of Cytopenias in Patients with Myelofibrosis Adapted to the Portuguese RealityActa Med Port2026 Oct 1PMID 42874039Guideline
- Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in ProgressOnco Targets Ther2026PMID 42846649
More hematology trends
All specialties →CAR-T in blood cancers
Chimeric antigen receptor T-cell therapy in lymphoma, myeloma and leukaemia.
Key point: CAR T-cell therapy has emerged as an effective option for refractory or progressive mantle cell lymphoma after prior covalent BTK inhibitor treatment.
Immune thrombocytopenia
ITP and its newer treatments.
Key point: Adult ITP care incorporates newer thrombopoietin receptor agonists and small molecule kinase inhibitors, emphasizing thrombotic risk and quality of life.
DOACs in cancer-associated thrombosis
Direct oral anticoagulants for venous thromboembolism in people with cancer.
Post-transplant cyclophosphamide
Cyclophosphamide after stem cell transplant to prevent graft-versus-host disease.
Key point: Post-transplant cyclophosphamide appears to reduce graft-versus-host disease without increasing relapse or mortality in matched related donor transplantation for acute leukemia.
Haemophilia
Haemophilia and its newer treatments, including gene therapy and non-factor drugs.
Targeted therapy in CLL
BTK and BCL2 inhibitors in chronic lymphocytic leukaemia.
Key point: In CLL/SLL, treatment selection is tailored based on age, genetic risk and comorbidities, prioritizing zanubrutinib, acalabrutinib and venetoclax-based regimens.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
myelofibrosis[tiab] AND (ruxolitinib[tiab] OR momelotinib[tiab] OR pacritinib[tiab] OR fedratinib[tiab] OR navitoclax[tiab] OR pelabresib[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.